Navigation Links
Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Date:3/8/2011

VERNON HILLS, Ill., March 8, 2011 /PRNewswire/ -- Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has received an Orphan Drug Designation from the FDA's Office of Orphan Products Development for its Mucin 1 (MUC1) targeting peptide, GO-203-2c, for the treatment of pancreatic cancer.

Orphan Drug Designation, as granted by the US Orphan Drug Act, is for a product that treats a rare disease or condition affecting fewer than 200,000 people in the US. According to the National Cancer Institute, there are approximately 31,000 people diagnosed with pancreatic cancer in the US annually, and approximately 220,000 worldwide. Orphan Drug Designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.  

"Treatment of pancreatic cancer represents a significant unmet medical need," said Stephen Thompson, CEO and President of Genus Oncology. "Pancreatic cancer is the fourth most common cause of cancer-related deaths in the Western world, and survival rates of patients diagnosed with pancreatic cancer have not changed in decades despite advances in treatment options. Based on our results of treating pancreatic cancer in preclinical models, we believe our MUC1 targeting technologies have the potential to significantly impact the treatment and outcomes of this difficult to treat disease."

GO-203-2c, Genus' lead drug candidate, is currently being studied in a Phase I trial that is designed to determine the safety and tolerability, and potential anti-tumor activity of the drug. The sites currently contracted to conduct the Phase I trial are the University of Texas Health Science Center at San Antonio (UTHSCSA) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare. Additional sites are currently under consideration.

About GO-203-2c

GO-203-2c is the optimized lead peptide drug candidate from a series of first-in-class agents synthesized to target MUC1, an oncoprotein that is overexpressed in many diverse human carcinomas including breast, prostate, lung, colon, pancreatic, and ovarian that have been associated with poor prognosis. Of an estimated 1.4 million cancer cases diagnosed each year in the US, about 900,000 overexpress MUC1, thus making it an attractive target for developing anti-cancer drugs. To date, there are no approved agents that target MUC1.

About Genus Oncology, LLC

Genus Oncology, LLC, is a clinical-stage company formed in 2007 with a mission of discovering, developing, and commercializing new anti-cancer agents that target the MUC1 oncoprotein. Genus' intellectual capital includes more than 20 years of research at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, and a senior management team with significant pharmaceutical industry experience leading successful discovery, development, and commercialization initiatives. For more information, please visit www.genusoncology.com.


'/>"/>
SOURCE Genus Oncology, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):